Genome-wide Polygenic Risk Scores Predict Risk of Glioma and Molecular Subtypes.
Taishi NakaseGeno A GuerraQuinn T OstromTian GeBeatrice MelinMargaret WrenschJohn K WienckeRobert B JenkinsJeanette E Eckel-Passownull nullMelissa L BondyStephen S FrancisLinda KachuriPublished in: medRxiv : the preprint server for health sciences (2024)
mutation status. Additionally, we provide refined estimates of individual genetic susceptibility and show that risk scores in the highest percentiles of the PRS distribution confer significant increases in relative and lifetime absolute risk. Taken together, our findings provide further evidence of the potential for germline genotyping to be used as a clinical biomarker in the assessment of personalized glioma risk and the non-invasive management of patients with newly diagnosed brain tumors.